Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Anticoagulation lowers subclinical leaflet thrombosis after TAVI procedure

31

Aug 2026

Anticoagulation lowers subclinical leaflet thrombosis after TAVI procedure

After transcatheter aortic valve implantation (TAVI), anticoagulation reduced imaging signs of clot formation on the new valve compared with antiplatelet therapy, without compromising safety. This was the main finding of the ACASA-TAVI trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in JAMA.

A personalized elimination diet changed the gut microbiome in people with migraine

31

Aug 2026

A personalized elimination diet changed the gut microbiome in people with migraine

In a 12-week randomized, sham-controlled trial of 98 adults with migraine, eliminating IgG-positive foods altered gut microbial composition and produced a greater reduction in serum zonulin than a sham elimination diet. The microbial changes were associated with previously reported reductions in CGRP and IL-6 and improvements in migraine and sleep, although the authors emphasized that these mechanistic links remain exploratory.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.